Guilin Pharmaceutical
China 76 employees 2 duplicate records merged Updated 9 July 2026
Guilin Pharmaceutical is a finished-dose manufacturer based in China. It holds one active US drug master file. Its filings concentrate with NAFDAC (NG), TMDA (TZ) and NPRA (MY). Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 18 August 2023 as NAI.
1
registered plants
1 with an FDA FEI number
26
filings
across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 18 August 2023 NAI US FDA
- 19 July 2018 VAI US FDA
- 13 March 2015 VAI US FDA
- 2 September 2011 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| China, China | 3002807125 |
What they file, and where
| Molecule | Regulators | Docs |
| Bumetanide | US FDA | 1 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| NAFDAC (NG) | 21 | None |
| TMDA (TZ) | 4 | None |
| NPRA (MY) | 1 | None |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Guilin Pharmaceutical comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was NAI, on 18 August 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates